Sunshine Biopharma (SBFMW) Cash from Investing Activities (2015 - 2026)
Sunshine Biopharma (SBFMW) reported Cash from Investing Activities of -$104518.0 for Q1 2026, up 50.7% on a YoY basis from -$69353.6 in Q1 2025, and down 108.17% quarter-over-quarter from -$50209.0 in Q4 2025.
Sunshine Biopharma (SBFMW) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Sunshine Biopharma has reported Cash from Investing Activities for 11 years, with the latest figure at -$104518.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 50.7% year-over-year to -$104518.0; the trailing twelve-month figure through Mar 2026 stood at -$728807.0 (up 52.13% YoY), and the FY2025 full-year result was -$836306.0, up 57.75% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$104518.0, down from -$50209.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $18859.0 in Q3 2023, with the low at -$14.6 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$1.3 million across 5 years, with a median of -$235746.5 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 98.16% — and 2024, when it slumped 3655.86%.
- Sunshine Biopharma's Cash from Investing Activities stood at -$14.6 million in 2022, then jumped by 98.16% to -$269230.0 in 2023, then jumped by 63.69% to -$97770.0 in 2024, then surged by 48.65% to -$50209.0 in 2025, then slumped by 108.17% to -$104518.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$104518.0 (Q1 2026), -$50209.0 (Q4 2025), and -$118295.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | -506.20 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | - |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | 25.99 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | -2.83 Mn |
| 10 | Sunshine Biopharma | - | - | 2.18 Mn | -104,518.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -104,518.00 |
| Mar 31, 2026 | -104,518.00 |
| Dec 31, 2025 | -50,209.00 |
| Dec 31, 2025 | -50,209.00 |
| Sep 30, 2025 | -118,295.00 |
| Sep 30, 2025 | -118,295.00 |
| Jun 30, 2025 | -455,785.00 |
| Jun 30, 2025 | -455,785.00 |
| Mar 31, 2025 | -212,017.00 |
| Mar 31, 2025 | -212,017.00 |
| Dec 31, 2024 | -97,770.00 |
| Dec 31, 2024 | -97,770.00 |
| Sep 30, 2024 | -670,599.00 |
| Sep 30, 2024 | -670,599.00 |
| Jun 30, 2024 | -542,208.00 |
| Jun 30, 2024 | -542,208.00 |
| Mar 31, 2024 | -668,736.00 |
| Mar 31, 2024 | -668,736.00 |
| Dec 31, 2023 | -269,230.00 |
| Dec 31, 2023 | -269,230.00 |